Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | LIPE | Q05469 | 8/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24629788 | 1.00 | EPHX2 (0.46) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| SCHEMBL29278592 | 1.00 | EPHX2 (0.46) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| Hydrochloric Acid SCHEMBL30152368 | 0.98 | EPHX2 (0.46) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| SCHEMBL30805661 | 0.86 | EPHX2 (0.51) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| SCHEMBL649932 | 0.86 | EPHX2 (0.51) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| SCHEMBL23207707 | 0.86 | EPHX2 (0.51) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| SCHEMBL647981 | 0.86 | EPHX2 (0.51) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| Hydrochloric Acid SCHEMBL23167679 | 0.85 | EPHX2 (0.50) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| Hydrochloric Acid SCHEMBL23167614 | 0.85 | EPHX2 (0.50) | EPHX2LIPELIPGKMT2AHSD11B1 | |
| SCHEMBL26799025 | 0.84 | POLB (0.41) | EPHX2LIPELIPGHSD11B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117480169-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4274660-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
| WO-2022150560-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150560-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | EPHX2 1579/4885LIPE 2041/4885LIPG 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.